Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We report the first in vitro and genetic confirmation of Malarone (GlaxoSmithKline; atovaquone and proguanil hydrochloride) resistance in Plasmodium falciparum acquired in Africa. On presenting with malaria two weeks after returning from a 4-week visit to Lagos, Nigeria without prophylaxis, a male patient was given a standard 3-day treatment course of Malarone. Twenty-eight days later the parasitaemia recrudesced. Parasites were cultured from the blood and the isolate (NGATV01) was shown to be resistant to atovaquone and the antifolate pyrimethamine. The cytochrome b gene of isolate NGATV01 showed a single mutation, Tyr268Asn which has not been seen previously.

Original publication

DOI

10.1186/1475-2875-1-1

Type

Journal article

Journal

Malar J

Publication Date

08/02/2002

Volume

1

Keywords

Amino Acid Substitution, Animals, Antimalarials, Atovaquone, Codon, Cytochromes b, Drug Combinations, Drug Resistance, Humans, London, Malaria, Falciparum, Male, Middle Aged, Mutation, Missense, Naphthoquinones, Nigeria, Parasitemia, Plasmodium falciparum, Proguanil, Protozoan Proteins, Travel